Roles of Endogenous Retroviruses in Cancer and Auto-immune Diseases

内源性逆转录病毒在癌症和自身免疫性疾病中的作用

基本信息

项目摘要

Approximately 8% of the genomes of mammals, including humans and mice, are comprised of retroviral elements acquired by infection of germ line cells during the course of evolution. Retroviral insertions in our genome number about 40,000 and are in the same range as the total number of genes encoded by our DNA. Most endogenous retrovirus elements are defective for replication however several contain one or more viral genes that are expressed during development and certain physiological or pathological conditions. Little is known about the control of retrovirus expression or the influence of such expression on the physiology or pathology of the host. An extensively investigated group of endogenous retroviruses are those giving rise to recombinant murine leukemia viruses (MuLVs) in mice. Upon infection of mice with exogenous ecotropic MuLVs, members of this group undergo recombination to generate new MuLVs with an altered infectious host range. Recombination requires transcription of the endogenous retroviruses. Although the endogenous polytropic proviruses are transcribed; replication of the endogenous polytropic viruses in the absence of recombination has not been observed. This may, in many cases, reflect defects such as point mutations or deletions in the endogenous viral genome but may also be influenced by the activity of various restriction factors. The fact that exogenous MuLVs are capable of replicating in mice indicates that they have evolved mechanisms to circumvent the activity of at least some of the restriction factors such as the murine APOBEC3. Thus, exogenous retroviruses might facilitate through complementation, active replication of endogenous retroviruses. We have found that infection of mice by an exogenous virus results in the infectious transfer of complete endogenous proviral genetic sequences. This includes proviruses which are severely defective and possess large deletions as well as proviruses that are full-length. Furthermore, the transferred sequences are transcribed and packaged into virions released from the newly infected cells. At early times after infection with the Friend MuLV, packaging and transfer of intact endogenous retroviruses is much more prevalent than recombination. Transfer of endogenous retroviruses can be observed as early as one day after infection indicating that packaging occurs after a single replication cycle in the initially infected cells of the host. In addition, we have found that other endogenous viruses, distinct from polytropic MuLVs, are likely mobilized from infected mice. The mobilization of intact endogenous retroviruses is unprecedented and may have important implications for the involvement of endogenous retroviruses in disease processes. In 2011 we have extended our observations to further characterize the endogenous viruses mobilized after infection by exogenous retroviruses. We have found a striking similarity of the viruses we have characterized with those mouse retroviruses reported to be contaminants in studies of putative mouse retrovirus infection in humans. Exogenous mouse retroviruses as well as some other gamma retroviruses, encode a glycosylated gag protein (gGag) originating from an alternate translation start site upstream of the methionine start site of the gag structural polyproteins. The functions of gGag remain unclear, but mutations that eliminate its synthesis severely impede in vivo replication of the virus with little, if any, effect on replication in fibroblastic cell lines. APOBEC proteins have evolved as innate defenses against retroviral infections. HIV encodes the VIF protein to evade human APOBEC3G, however mouse retroviruses do not encode a VIF homologue and it has not been understood how they evade mouse APOBEC3. We have found that a mouse retrovirus utilizes its glycosylated gag protein (gGag) to evade APOBEC3. gGag is critical for infection of in vitro cell lines in the presence of APOBEC3. Furthermore, a gGag-deficient virus restricted for replication in wild-type mice replicates efficiently in APOBEC3 knockout mice implicating a novel role of gGag in circumventing the action of APOBEC3 in vivo. In 2011 we have focused on the elucidation of the mechanism by which the gGag protein abrogates the action of APOBEC3. To counteract the human APOBEC3G (hA3g), HIV has evolved the Vif protein, which depletes hA3g from infected cells by facilitating its degradation through the proteosome. We have found that a gGag-containing MuLV does not deplete mA3 from an infected cell. Further, immunoprecipitation and localization experiments suggest that mA3 does not interact with gGag directly in an infected cell. In contrast, both gGag and mA3 are associated with the virion core and are coprecipitated in the context of the mature virions. Both hA3g and mA3 have been reported to use deamination-dependent and -independent mechanisms to inhibit retroviral replication. Inhibition by mA3 on gGag-deficient virions correlates with a decrease in the level of transcripts upon infection of cells and appears largely independent of deamination activity. The endogenous retroviral envelope glycoprotein, gp70 is implicated in murine lupus nephritis. This protein is secreted by hepatocytes as an acute phase protein and has been believed to be a product of an endogenous xenotropic virus. However, since endogenous polytropic viruses encode gp70s that are closely related to xenotropic gp70, these viruses could be additional sources of serum gp70. To better understand the genetic basis of the expression of serum gp70, we analyzed the abundance of xenotropic and polytropic gp70 RNAs in livers and the genomic composition of corresponding endogenous proviruses in various strains of mice, including two different Sgp (serum gp70 production) congenic mice (Sgp3 and Sgp4). These studies revealed a significant contribution of polytropic gp70s to serum gp70. These studies were extended to show that expression levels of a subclass of polytropic MuLVs, termed, modified polytropic (mPT), are highly elevated in mice which develop systemic lupus erythematosus. This elevated expression appears specific for this class of endogenous viruses and under the control of the Sgp3 locus. We have also examined the influence of TLR7 or TLR9 agonist on the expression of serum gp70s. These results suggest an additional pathogenic role of TLR7 and TLR9 in murine lupus nephritis by promoting the expression of nephritogenic gp70 autoantigen. In 2011 we have extended these results to determine the genetic origin of xenotropic viral sequences expressed in wild-type and two different Sgp congenic C57BL/6 mice. The results of these indicated that Sgp3 and Sgp4 independently regulated the transcription of distinct and restricted sets of xenotropic viral sequences in trans, thereby promoting the production of nephritogenic gp70 autoantigens. Among these endogenous viruses induced by Sgp3 and Sgp4 are two potentially replication competent xenotropic viruses. Although xenotropic viruses cannot infect mouse cells it is possible that these viruses may be complemented by mPT env proteins allowing their spread and and activation of TLR 7. In this regard, the presence of Sgp3 induces an approximately 100-fold increase of mPT viruses. Thus Sgp3 and Sgp4 may contribute to the development of autoimmune responses against serum gp70 through the activation of TLR7.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LEONARD EVANS其他文献

LEONARD EVANS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LEONARD EVANS', 18)}}的其他基金

Genetic Structure Of Murine Retroviruses
鼠逆转录病毒的遗传结构
  • 批准号:
    6984876
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Roles of Endogenous Retroviruses in Cancer and Auto-immune Diseases
内源性逆转录病毒在癌症和自身免疫性疾病中的作用
  • 批准号:
    8556012
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Roles of Endogenous Retroviruses in Cancer and Auto-immune Diseases
内源性逆转录病毒在癌症和自身免疫性疾病中的作用
  • 批准号:
    8946483
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Genetic Structure Of Murine Retroviruses
鼠逆转录病毒的遗传结构
  • 批准号:
    7190182
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Genetic Structure Of Murine Retroviruses
鼠逆转录病毒的遗传结构
  • 批准号:
    6531637
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Influence of Mixed Retrovirus Infections on Leukemia and Neurological disease
逆转录病毒混合感染对白血病和神经系统疾病的影响
  • 批准号:
    7964217
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Influence of Mixed Retrovirus Infections on Leukemia and Neurological disease
逆转录病毒混合感染对白血病和神经系统疾病的影响
  • 批准号:
    8555741
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Genetic Structure Of Murine Retroviruses
鼠逆转录病毒的遗传结构
  • 批准号:
    7299909
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
GENETIC STRUCTURE OF MURINE RETROVIRUSES
鼠逆转录病毒的遗传结构
  • 批准号:
    6288818
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:
Influence of Mixed Retrovirus Infections on Leukemia and Neurological disease
逆转录病毒混合感染对白血病和神经系统疾病的影响
  • 批准号:
    8156819
  • 财政年份:
  • 资助金额:
    $ 62.84万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 62.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 62.84万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 62.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了